Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 May;57(5):638-41.
doi: 10.11406/rinketsu.57.638.

[Development of myelofibrosis during eltrombopag treatment in a patient with immune thrombocytopenia]

[Article in Japanese]
Akira Horikoshi  1 , Jumpei Tsukuda, Ryouhei Abe, Naoki Fujiwara, Eisaku Ito, Tomoo Takaku
Affiliations
Case Reports

[Development of myelofibrosis during eltrombopag treatment in a patient with immune thrombocytopenia]

[Article in Japanese]
Akira Horikoshi et al. Rinsho Ketsueki. 2016 May.

Abstract

Eltrombopag, a thrombopoietin (TPO) receptor agonist, is effective for treating refractory immune thrombocytopenia (ITP). However, the development of bone marrow fibrosis is a concern. A 78-year-old man was diagnosed with ITP in 2004. His platelet count did not increase after eltrombopag treatment initiation in 2014. However, anemia progressed, along with the presence of immature myelocytes, erythroblasts, and tear drop cells. At 8 months after initiating eltrombopag treatment, the patient underwent a bone marrow biopsy that showed grade 2 myelofibrosis. Hence, eltrombopag was discontinued. In our experience with this case indicates that careful observation is required while using TPO receptor agonists.

PubMed Disclaimer

Publication types